TNFRSF17 and Miyoshi myopathy: It is a humanized bispecific mAb whose mechanism of action involves binding to BCMA on plasma cells, MM cells, and plasmablasts and also binding to CD3 on T-cells, inducing T-cell-mediated on MM cells [105,106,107].